Neuroendocrine and Adrenal Tumors

University of Pennsylvania

Overview

This is a prospective study of rare neuroendocrine and adrenal tumors. Subjects will be enrolled via informed consent, and blood and/or saliva and tissue will be collected. This is designed to work in conjunction with IRB#831990 which is a retrospective protocol. The University of Pennsylvania will be a contributing site with the University of Michigan as the coordinating site for the A5 alliance, a multi-institutional collaborative designed to study neuroendocrine and adrenal tumors.

Study Type

OBSERVATIONAL

Conditions

Neuroendocrine Tumors Adrenal Tumor

Interventions

No interventionOTHER

There are no interventions

Eligibility

Sex: ALLMin age: 18 YearsMax age: 90 Years

Medical Language ↔ Plain English

Inclusion Criteria: * diagnosed with neuroendocrine and/or an adrenal tumor Exclusion Criteria: * pregnant women * prisoners * people under the age of 18

Outcomes

Primary Outcomes

Survival

Time frame: 10 years

Secondary Outcomes

Tumor Recurrence

We want to record recurrences in our patient population

Time frame: 10 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.